Treatment of Mycobacterium avium complex infection: Do the results of in vitro susceptibility tests predict therapeutic outcome in humans?

Journal of Infectious Diseases

Volumn 173, Issue 3, 1996, Pages 677-683

  Sison, Jeanette P ^b   Yao, Yizhong ^b   Kemper, Carol A ^a   Hamilton, John R ^b   Brummer, Elmer ^b   Stevens, David A ^b   Deresinski, Stanley C ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CLOFAZIMINE; ETHAMBUTOL; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030021732     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.3.677     Document Type: Article

References (5)

1. Kemper CA, Havlir D, Haghighat D, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994;170:157-64.
2. Havlir D, Kemper C, Deresinski SC. Reproducibility of the lysis-centrifugation techniques for quantification of Mycobacterium avium complex bacteremia. J Clin Microbiol 1993;31:1794-8.
3. Gill VJ, Park CH, Stock F, Gosey LL, Witebsky FG, Masur H. Use of lysis-centrifugation (Isolator) and radiometric (BACTEC) blood culture systems for the detection of mycobacteria. J Clin Microbiol 1985;22:543-6.
4. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing proposed standard. Villanova, PA: NCCLS, 1992; document M24-P.
5. Wallace RJ Jr, Nash DR, Steele LC, Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986;24:976-81.